

**GENERIC MEDICINES: ASSESSMENT OF THE  
KNOWLEDGE AND PERCEPTIONS OF  
MEDICAL SPECIALISTS AND GENERAL  
PRACTITIONERS IN MALAYSIA**

**ROHIT KUMAR**

**UNIVERSITI SAINS MALAYSIA  
2015**

**GENERIC MEDICINES: ASSESSMENT OF THE  
KNOWLEDGE AND PERCEPTIONS OF  
MEDICAL SPECIALISTS AND GENERAL  
PRACTITIONERS IN MALAYSIA**

**By**

**ROHIT KUMAR**

**Thesis submitted in fulfillment of the requirements  
for the degree of  
Doctor of Philosophy**

**March 2015**

**DEDICATED TO MY LORD KRISHNA, MY FAMILY  
AND  
ALL RESEARCHERS**

## **ACKNOWLEDGEMENT**

This work began as a result of a conversation with Prof. Dr. Mohamed Azmi Ahmad Hassali regarding usage of generics in Malaysia. He expressed his concern about the low confidence of physicians in generics. He also explained about his department's efforts to promote generics and various studies being undertaken by them to put forward the views of community pharmacists, consumers and prescribers about generics in Malaysia. He also expressed his deep concern regarding access to private hospitals in Malaysia to conduct such a study. I asked him about the possibility of conducting this research for my PhD and he warned me about the challenges which we might face as many private hospitals, physicians working in these hospitals might not be open or interested to participate. We together took this challenge and initiated this work.

Personally, I would like to express my sincere gratitude to Prof. Dr. Mohamed Azmi Ahmad Hassali. You have been an incredible supervisor and mentor. I am fortunate that you accepted me as your student and I came across such a dynamic personality who is so passionate and aggressive in his field. I have learned a great deal under your guidance and I appreciate all the hard work you have put into helping me complete this degree. You have been supportive, understanding, and positive.

I would also like to thank Dr. Muhamad Ali bin Skeikh Abdul Kader and Dr. Fahad Saleem for being my co-supervisors during this tenure. I would also like to thank Professor Dr. Munavvar Abdul Sattar, Dean, School of Pharmaceutical Sciences, for his encouragement, advice, and support.

Special thanks to Dr. Alian A. Alrasheedy, Mr. Ashutosh Verma, Mr. Zhi Yen Wong, and other faculty members of Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia who contributed either directly or indirectly throughout the progress of my research work. Very special thanks to my ex-boss Mr. Jeyabalan T. from Ranbaxy (Malaysia) Sdn. Bhd., whose constant support in many ways led me to complete this work. I owe him a lot for his kind gestures.

I owe a debt of gratitude to all the respondents who took time out of their busy schedule to participate in this study. I really enjoyed traveling to many places in different part of Malaysia for interviewing doctors. This not only helped me completing my work but also gave me knowledge about the great culture of this country.

I would like to thank my wife, Navneet who supported me during this research as a fellow researcher, motivated me to visit hospitals, accompanied me and took all pains during my tough times. Finally, I would like to thank my children, Aasheen and Eshaan, for being such loving and independent kids, enabling me to complete this work. Last but not the least, I would like to thank those powers who were behind the scenes like my parents for their love, and incredibly great confidence in me.

## TABLE OF CONTENTS

<b>Title</b>	<b>Page</b>
<b>ACKNOWLEDGEMENT</b>	<b>ii</b>
<b>TABLE OF CONTENTS</b>	<b>iv</b>
<b>LIST OF TABLES</b>	<b>ix</b>
<b>LIST OF FIGURES</b>	<b>x</b>
<b>ABBREVIATIONS</b>	<b>xi</b>
<b>LIST OF APPENDICES</b>	<b>xiv</b>
<b>LIST OF PUBLICATION</b>	<b>xv</b>
<b>ABSTRAK</b>	<b>xvi</b>
<b>ABSTRACT</b>	<b>xviii</b>
<b>CHAPTER ONE: GENERAL INTRODUCTION</b>	<b>1</b>
1.1 Background	2
1.2 Generic Medicines	5
1.2.1 Overview of Generic Drug Product Development Processes	13
1.2.2 Are Generics Really the Same as the Originator Products?	16
1.2.2.1 Generic Substitution	19
1.3 Problem Statement	27
1.3.1 Justification for the Research	31
1.3.2 Research Objectives	32
1.3.3 Significance of the Study	33
1.3.4 Thesis Overview	34
<b>CHAPTER TWO: LITERATURE REVIEW</b>	<b>36</b>
2.1 Healthcare System in Malaysia	37
2.1.1 Malaysian Healthcare System: A Brief Overview	37
2.1.2 Healthcare System Organisation and Provision of Health Care	39
2.1.3 Healthcare Insurance in Malaysia	43
2.1.4 Healthcare System Expenditure and Financing	45

2.1.5	Sources of Revenue for the Healthcare System	49
2.1.6	The Malaysian Pharmaceutical Industry	50
	2.1.6.1 The Patented Drug Market of Malaysia	55
	2.1.6.2 The Generic Drug Market of Malaysia	57
2.1.7	Registration of Pharmaceutical Products in Malaysia	59
	2.1.7.1 Registration of Generic Medicines in Malaysia: Bioequivalence	61
2.2	Problems Associated with the Malaysian Healthcare System	64
2.3	Issues Related to Generic Medicines use in Malaysia – Physicians’ Perspectives	70
 <b>CHAPTER THREE: METHODOLOGICAL CONSIDERATIONS FOR MIXED METHOD RESEARCH</b>		<b>73</b>
3.1	Introduction	74
3.2	Perceptions	74
3.3	Methods of Assessing Attitudes, Perceptions and Behaviour	75
	3.3.1 Qualitative Research Methods	75
	3.3.1.1 Research Strategy	77
	3.3.1.2 Sampling Strategy and Size	83
	3.3.1.3 Data Collection Methods	85
	3.3.1.4 Data Analysis	89
	3.3.1.5 Products of Qualitative Research	90
	3.3.1.6 The Challenges in Qualitative Research	91
	3.3.2 Quantitative Research Method	92
	3.3.2.1 Questionnaire Based Survey Design	93
	3.3.2.2 Sampling Technique and Sample Size	96
	3.3.2.3 Questionnaire Discrimination, Validity and Reliability	98
	3.3.2.4 Data Analysis	104
3.4	Mixed Methods of Research	106

<b>CHAPTER FOUR: QUALITATIVE ASSESSMENT OF THE KNOWLEDGE AND PERCEPTIONS TOWARDS GENERIC MEDICINES AMONG PRIVATE MEDICAL SPECIALISTS IN MALAYSIA</b>	<b>109</b>
4.1 Introduction	110
4.2 Objectives	110
4.3 Methods	111
4.3.1 Study Design, Study Population and Sample Strategy	111
4.3.2 Development of Interview Guide & Interview Settings	112
4.3.3 Data Collection and Management	113
4.3.4 Data Analysis and Reporting	114
4.3.5 Ethical Considerations	114
4.4 Results	115
4.4.1 The Demographic Data of the Participants	115
4.4.2 Theme Generation	116
4.4.2.1 Theme 1: Prescription Patterns	116
4.4.2.2 Theme 2: Awareness and Trust of Generics	118
4.4.2.3 Theme 3: The Reception of Generics by Patients	124
4.4.2.4 Theme 4: The Effect of Drug Promotion and Marketing on the Selection of Prescription Medicine	127
4.4.2.5 Theme 5: Brand Substitution by Hospital Pharmacists	128
4.4.2.6 Theme 6: Strategies to Increase the Rate of Generic Prescribing	129
4.5 Discussion	130
4.6 Conclusion	134
4.7 Limitations of the Study	135
<b>CHAPTER FIVE: QUANTITATIVE ASSESSMENT OF THE KNOWLEDGE AND PERCEPTIONS TOWARDS GENERIC MEDICINES AMONG PRIVATE MEDICAL SPECIALISTS IN MALAYSIA</b>	<b>136</b>
5.1 Introduction	137
5.2 Objectives	137
5.3 Methods	138



5.3.1	Study Design	138
5.3.1.1	Study Instrument/Questionnaire	138
5.3.1.2	Study Participants and Sampling	139
5.3.1.3	Study Administration	139
5.3.1.4	Statistical Analysis	140
5.4	Results	141
5.4.1	Demographic and Practice Characteristics	141
5.4.2	The Doctor's Knowledge about the Regulatory Bioequivalence Standard for Generic Drug Products	143
5.4.3	Prescription Behaviour of Physicians	144
5.4.4	Knowledge about Generic Medicines	144
5.4.5	The Perceptions of the Prescribers to issues pertaining to Generic Medicines Utilisation	147
5.5	Discussion	154
5.6	Conclusion	159
5.7	Limitations of the Study	160
 <b>CHAPTER SIX: IMPACT OF INTERVENTION STUDY ON THE KNOWLEDGE AND PERCEPTIONS TOWARDS GENERIC MEDICINES AMONG MEDICAL SPECIALISTS AND GENERAL PRACTITIONERS IN MALAYSIA</b>		<b>161</b>
6.1	Introduction	162
6.2	Group Educational Interventions	162
6.3	Objectives	164
6.4	Methods	164
6.5	Statistical Analysis	165
6.6	Results	166
6.6.1	Demographic and Practice Characteristics	166
6.6.2	The Doctor's Knowledge about the Regulatory Bioequivalence Standards for Generic Drug Products	166
6.6.3	Prescription Behaviour of Physicians	168
6.6.4	The Knowledge about Generic Medicines	168
6.6.5	The Perceptions of the Prescribers to Issues Pertaining to Generic Medicines Utilisation	171
6.7	Discussion	172

6.8	Conclusion	174
6.9	Limitations of the Study	175
<b>CHAPTER SEVEN: THESIS CONCLUSION AND RECOMMENDATIONS</b>		<b>176</b>
7.1	Introduction	177
7.2	Thesis Conclusion	178
7.3	Future Recommendations	183
7.4	Recommendations for Future Research	186
<b>REFERENCES</b>		
<b>APPENDICES</b>		

## LIST OF TABLES

		<b>Page</b>
Table 2.1	Public Health Expenditure by the Source of Financing, 2009	50
Table 3.1	Flow Chart for Development of Questionnaire (Study Instrument)	95
Table 4.1	The Physician's Demographic Characteristics (Qualitative Study)	115
Table 5.1	Demographic and Practice Characteristics of Participants (Quantitative Study)	142
Table 5.2	The Knowledge about Generic Medicines (Quantitative Study)	148
Table 5.3	The Comparison between Demographic Characteristics & the Knowledge towards Generic Medicines (Quantitative Study)	149
Table 5.4	The Perceptions of Prescribers to Issues Pertaining to Generic Medicines Utilization (Quantitative Study)	152
Table 5.5	The Comparison between Demographic Characteristics on a Doctor's Perceptions about Issues Pertaining to Generic Medicines Utilization (Quantitative Study)	153
Table 6.1	The Doctor's Demographic Characteristics (Intervention Study)	167
Table 6.2	The Doctor's Knowledge about Regulatory Bioequivalence Standards for Generic Medicines in Malaysia (Intervention Study)	168
Table 6.3	The Frequency of Prescribing Brand Names Drugs (Intervention Study)	168
Table 6.4	The Effect of an Intervention on the Doctor's Knowledge about Generic Medicines (Intervention Study)	170
Table 6.5	The Effect of an Intervention on a Doctor's Perception to Issues Pertaining to Generic Medicines Utilisation (Intervention Study)	171

## LIST OF FIGURES

		<b>Page</b>
Figure 1.1	Spending on Medicines in the US (2001-2010)	3
Figure 1.2	Healthcare Expenditure will Continue to Outpace GDP and Wages	4
Figure 1.3	Generics Savings over the Course of Time in the USA	10
Figure 1.4	Generics Market Share of the Outpatient Market in the EU (% Volume)	11
Figure 1.5	Schematic of the Drug Development Process	16
Figure 2.1	Geographical Location of Malaysia	38
Figure 2.2	Trends for Total Health Expenditure, 1997 – 2012 (RM mn & GDP)	45
Figure 2.3	Adjusted per Capita Spending on Health, 1997 - 2012 (RM)	46
Figure 2.4	The Pharmaceutical Market Forecast for 2009-2023	53
Figure 2.5	Patented Drug Market Forecast for 2009-2023	56
Figure 2.6	Generic Drug Market Forecast for 2009-2023	58
Figure 2.7	Private Healthcare Expenditure (Constant value), Malaysia, 1997-2009	66
Figure 2.8	OOPPs (Constant value) and OOPPs as a % of GDP, Malaysia, 1997-2006	67
Figure 2.9	Private Share of the Total and the OOPPs Share of Private Expenditure with an International Comparison, 2009 (%)	68
Figure 2.10	Private Sector Health Expenditure by Sources of Funding, 2012 (RM, mn)	69
Figure 5.1	The Respondent's Knowledge about the Percent Test/Reference (%T/R) Ratio at a 90% Confidence Interval for a Bioequivalence Study [n=263]	143

## ABBREVIATIONS

%	Percentage
&	And
>	More Than
APHM	Association of Private Hospitals of Malaysia
API	Active Pharmaceutical Ingredient
APPL	Approved Products Price List
ASEAN	Association of South-East Asian Nations
AUC	Area Under Curve
BLA	Biologics License Application
BMI	Business Monitor International
bn	Billion
CAGR	Cumulative Annual Growth Rate
CCM	Chemical Company of Malaysia
cGMP	Current Good Manufacturing Practices
Cmax	Maximum Plasma Drug Concentration
CVS	Cardiovascular System
DALYs	Disability Adjusted Life Years
DCA	Drug Control Authority
DES	Drug-Eluting Stent
EC	European Commission
edn.	Edition
EGA	European Generic Medicines Association
EIU	Economic Intelligence Unit
EMA	European Medicines Agency
EPF	Employee Provident Funds
EPP	Entry Point Project
EU	European Union
FDA	Food and Drug Administration
GDP	Good Distribution Practices
GDP	Gross Domestic Product
GMP	Good Manufacturing Practices
GPhA	Generic Pharmaceutical Association

GPs	General Practitioners
GRAS	Generally Regarded as Safe
GS	Generic Substitution
HRD	Human Resources Department
IND	Investigational New Drug
INN	International Non-Proprietary Name
KNMP	The Royal Dutch Pharmacists Association
LDL	Low Density Lipoprotein
LHS	Left Hand Side
LMICs	Lower and Middle Income Countries
MAA	Marketing Authorization Application
MACCE	Major Adverse Cardiovascular and Cerebrovascular Event
MIDA	Malaysian Industrial Development Authority
MITI	Ministry of International Trade and Industry
mn	Million
MNCs	Multinational Companies
MNHAs	Malaysia National Health Accounts
MOH	Ministry of Health
MOPI	Malaysian Organization of Pharmaceutical Industries
MSQH	Malaysian Society for Quality of Health
NCEs	New Chemical Entities
NDA	New Drug Application
NEDL	National Essential Drugs List
NHMS	National Health Morbidity Surveys
NKEAs	National Key Economic Areas
NPCB	National Pharmaceutical Control Bureau
NTI	Narrow Therapeutic Index
OIC	Organization of the Islamic Conference
OOPPs	Out-of-Pocket Payments
OTC	Over-the-counter
PBS	Schedule of Pharmaceutical Benefits
PhAMA	Pharmaceutical Association of Malaysia
PIC/S	Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme

PPP	Purchasing Power Parity
PSD	Pharmaceutical Services Division
QD	Qualitative Descriptive
R&D	Research and Development
RHS	Right Hand Side
RM	Ringgit Malaysia
SHI	Social Health Insurance
SOCSO	Social Security Organization
TEH	Total Health Expenditure
TPPA	Trans-Pacific Partnership Agreement
USA	United States of America
USFDA	United States Food and Drug Administration
WHO	World Health Organization
WTO	World Trade Organization

## LIST OF APPENDICES

- Appendix I Consent Form used in the Qualitative Study
- Appendix II Semi-Structured Interview Guide for Physicians
- Appendix III Ethical Committee Approval of the Research Project
- Appendix IV The Questionnaire used in the Quantitative Study of Physicians
- Appendix V Request Letter to the President of APHM
- Appendix VI Approval Letter from the President of APHM
- Appendix VII Request Letter for Survey to Hospitals
- Appendix VIII Publication
- Appendix IX Pre-Viva Presentation Certificate
- Appendix X Turnitin Screening Certificate
- Appendix XI Certificate of Proof Reading and Copy Editing



## LIST OF PUBLICATIONS

1. **Kumar, R.**, Hassali, M. A. A., Kaur, N. and Kader, M. A. S. A. (2014) Perceptions of physicians from private medical centres in Malaysia about generic medicine usage: a qualitative study, *Generics and Biosimilars Initiative Journal*, 3(2), 63-70.
2. **Kumar, R.**, Hassali, M. A., Saleem, F., Alrasheedy, A. A., Kaur, N., Wong, Z. Y. and Kader, M. A. S. A. (2015) Knowledge and perceptions of physicians from private medical centres towards generic medicines: A nationwide survey from Malaysia, *Journal of Pharmaceutical Policy and Practice* (In Press).

# **UBAT-UBATAN GENERIK: PENILAIAN PENGETAHUAN DAN PERSEPSI PAKAR-PAKAR DAN PENGAMAL PERUBATAN DI MALAYSIA**

## **ABSTRAK**

Dalam tahun-tahun kebelakangan ini, perbelanjaan farmaseutikal telah berkembang lebih cepat berbanding komponen lain yang berkaitan perbelanjaan penjagaan kesihatan. Secara global, tekanan untuk menguruskan perbelanjaan farmaseutikal telah membolehkan kerajaan dan organisasi kesihatan bukan kerajaan untuk menggalakkan penggunaan ubat-ubatan generik. Pada tahun 2012, perbelanjaan out-of-pocket (OOP) Malaysia terhadap penjagaan kesihatan adalah 79% daripada perbelanjaan sektor swasta dan ia adalah dua kali ganda tinggi bagi negara-negara berpendapatan tinggi out-of-pocket pembayaran (OOPPs), yang purata 37% daripada perbelanjaan sektor swasta. Untuk menurunkan OOPPs dan mengurangkan beban kewangan terhadap pesakit dalam sektor penjagaan kesihatan swasta, ia amat disyorkan untuk menggalakkan penggunaan generik. Di Malaysia, preskripsi ubatan generik telah menjadi satu amalan biasa di hospital kerajaan. Walau bagaimanapun, trend di hospital perubatan swasta Malaysia keadaannya seolah-olah berbeza. Tujuan kajian ini adalah untuk menyiasat pengetahuan pusat perubatan swasta Malaysia physicians', dan persepsi berhubung penggantian ubat-ubatan generik bagi produk asas. Kaedah rekabentuk penyelidikan campuran telah diguna pakai untuk kerja-kerja ini. Di bawah kajian kualitatif, lapan belas pakar perubatan daripada bidang perubatan yang berbeza telah ditemuramah. Majoriti pakar memberikan pandangan positif tentang penggantian generik tetapi sinis tentang kualiti mereka dari segi keberkesanan dan keselamatan bagi beberapa kategori dadah. Doktor lebih

suka untuk melihat keputusan biokesetaraan dijalankan oleh pengilang generik dan juga mereka lebih suka untuk menghias dengan beberapa kajian farmakodinamik berasaskan komuniti kecil. Kajian kuantitatif adalah satu kajian di seluruh negara yang melibatkan pakar-pakar perubatan dari pusat perubatan swasta di Malaysia. Secara keseluruhan, 263 jawapan diterima daripada hospital berbeza di Semenanjung dan Malaysia Timur. Respon yang telah diterima terdiri daripada penyertaan dari hospital kecil ke hospital besar dalam rangkaian Malaysia. Pelbagai persatuan yang ketara telah diperhatikan mengikut butir-butir demografi dan pengetahuan dan persepsi doktor mengenai generik. Selanjutnya, kajian intervensi pendidikan telah dijalankan untuk menilai kesan ke atas pengetahuan dan persepsi doktor terhadap ubat-ubatan generik. Terdapat sedikit peningkatan dalam pengetahuan diperhatikan selepas intervensi, yang disokong oleh pelbagai kajian, memastikan perubahan dalam tingkah laku, setiap kali pengetahuan mengenai generik telah disediakan. Kejayaan generik di pusat-pusat perubatan swasta di Malaysia bergantung kepada perubahan persepsi doktor mengenai ubat-ubatan generik. Selain pelaksanaan dasar penggunaan ubat generik untuk hospital swasta di Malaysia, ini juga boleh dicapai melalui pembaikan dalam pemasaran dan promosi produk generik yang lebih baik. Para doktor yang berkhidmat di hospital-hospital awam di Malaysia mungkin mempunyai pemahaman yang lebih baik mengenai ubat-ubatan generik, daripada mereka yang menjalankan amalan perubatan di sektor swasta, kerana kebanyakan ubat-ubatan yang diberi oleh hospital kerajaan adalah generik. Dalam sektor swasta, maklumat akademik boleh membantu meningkatkan pengetahuan doktor mengenai ubat-ubatan generik.

# **GENERIC MEDICINES: ASSESSMENT OF THE KNOWLEDGE AND PERCEPTIONS OF MEDICAL SPECIALISTS AND GENERAL PRACTITIONERS IN MALAYSIA**

## **ABSTRACT**

In recent years, pharmaceutical expenditure has grown faster than many of the other components of healthcare spending. Globally, pressure to manage pharmaceutical spending has led governments and non-governmental health organizations to promote the use of generic drugs. In 2012, Malaysia's out-of-pocket (OOP) expenditure on healthcare was 79% of private sector spending and it was twice the high income countries out-of-pocket payments (OOPPs), which average at 37% of private sector expenses. To bring down the OOPPs and reduce financial burden on patients in private healthcare sector, it is highly recommended to promote the use of generics. In Malaysia, generic drug prescribing has become a common practice in public hospitals. However, the trend in private medical centres of Malaysia seems to be different. The aim of this study was to investigate Malaysian private medical centers physicians' knowledge, and perceptions regarding substituting generic medications for originator products. Mix methods research design was adopted for this work. Under qualitative study, eighteen medical specialists from different medical fields were interviewed. The majority of specialists were positive about generic substitution but cynical about their quality in terms of efficacy and safety for some drug categories. Physicians preferred to see the results of bioequivalence conducted by generic manufacturers and also preferred them to garnish it with some small scale community based pharmacodynamic studies. The quantitative study was


a nationwide survey involving physicians from private medical centres in Malaysia. In total, 263 responses were received from different hospitals of Peninsula and East Malaysia. The responses received comprised of participation from small to big hospitals chains of Malaysia. Various significant associations were observed among physicians' demographic particulars and their knowledge and perceptions about generics. Further, an educational interventional study was carried out to evaluate the impact on the knowledge and the perceptions of physicians towards generic medicines. A slight improvement in knowledge was observed after the intervention, which was supported by various studies, assuring a change in behaviour, whenever the knowledge about generics was provided. The success of generics in private medical centres in Malaysia depends on changing the perceptions of these physicians about generic drugs. In addition to implementation of generic drug usage policy for private hospitals in Malaysia, this can also be achieved through improved marketing and promotion of generic products. The doctors serving in the public hospitals in Malaysia might have a better understanding about generic medications, than those who are practising in the private sector, since most of the medications dispensed by government hospitals are generics. In the private sector, academic detailing can help to improve the knowledge of physicians about generic medicines.

## **CHAPTER ONE: GENERAL INTRODUCTION**

## 1.1 Background

The expenditure on healthcare is steadily increasing in many countries around the globe. The World Health Organization (WHO) reported that 5.3 trillion dollars were spent on healthcare in 2007, which amounted to a sum of 6.5 trillion dollars in a recent fact sheet published by the agency (Xu, et al., 2010; WHO, 2012a). Although higher health expenditures cannot necessarily be linked with better health outcomes, a minimum level of resources are required for a healthcare system to fulfil its vital functions adequately. Moreover, with the increment in lifestyle diseases, such as hypertension, cardiovascular (CVS) diseases, cancer, and diabetes etc., national healthcare costs are increasing noticeably. In recent years, it has been reported that pharmaceutical expenditure is growing faster than many of the other components of healthcare spending (Henriksson, et al., 1999; Schneeweiss, et al., 2002; Ess, et al., 2003; Thorpe, K. E., 2005; Zuvekas, et al., 2007; Coma, et al., 2009; Leng, et al., 2011; Godman, et al., 2012a; Hoffman, et al., 2012; Hermansyah, A., 2013; Hoffman, et al., 2013). In the United States of America (USA), total spending on medicines in 2010 was \$307 billion (bn), an increase of around \$60bn since 2005 and \$135bn since 2001 (Figure 1.1).

Across Europe, healthcare is scarcely managing to cover its expenses. The rise in pharmaceutical expenditure is typically between 4% and 13% per annum (Heikkilä, et al., 2007; Simoens, S., 2009; Sermet, et al., 2010; Vandoros, et al., 2013). This rise is similar to the USA in its pace, especially when compared to the growth of other parts of healthcare expenditure (Schneeweiss, et al., 2002; Schneeweiss, et al., 2004).




**Figure 1.1 Spending on Medicines in the US (2001-2010)**  
 [Adapted and Modified from IMS Database, 2012]

The different ways of raising funds to cover healthcare costs are inadequate, but, of even greater concern, the costs themselves are set to ascend. According to World Bank statistics, public spending on healthcare in the European Union (EU) could shoot up from 8% of the gross domestic product (GDP) in 2000 to 14% in 2030 and keep on growing beyond that date. The dominant anxiety of the European healthcare sector is to discover new ways to balance its budgets and control spending. If that is not achieved, the resources to pay for healthcare will soon fall short of demand (The Future of Healthcare in Europe, 2011). All European governments are facing the same basic challenge: how to fund their own health-care systems without demanding too many sacrifices from the public. A survey conducted in 6 European healthcare systems: Switzerland, France, Germany, Italy, Spain and United Kingdom, reveals that overall healthcare expenditure has grown on average by about 80% in these countries since 1990, while the GDP of the group has grown by only about 25%



(Beyer, et al., 2007). This divergence is expected to continue during the coming decades (Figure 1.2).



**Figure 1.2 Healthcare Expenditure will Continue to Outpace GDP and Wages**  
[Adapted and Modified from Beyer, et al., 2007]

In the lower and middle income countries (LMICs), this expenditure ranges from 20% - 60% of the total spending on healthcare (Cameron, et al., 2009; Godman, et al., 2010a). In these countries, patented medicines generally cost considerably higher than their generic counter parts, and by example, they can go up 10 fold (WHO, 2010a; Cameron, et al., 2012; GaBI Online, 2014). Overall, insurance coverage in the LMICs remains poor and many schemes do not cover expenses on medicines. Hence, medicines are still mainly purchased through out-of-pocket payments (OOPPs) in the private sector. Globally, pressure to manage pharmaceutical spending has led governments and non-governmental health organizations to promote the use

of generic drugs (De Joncheere, et al., 2002; Simoens, et al., 2006; Simoens, S., 2007; Araszkievicz, et al., 2008; Sermet, et al., 2010; Godman, et al., 2012b). European health authorities, and health insurance companies, have instigated a number of reforms and initiatives in recent years to deal with this unsustainable growth. Among the many efforts made by them include a focus on the policies surrounding generics, to result in providing high quality treatment at lower prices, with considerable savings (Seeley, E. 2008; Seeley, et al., 2008; Figueiras, et al., 2009; Ministry of Health, Labour and Welfare of Japan, 2012).

## **1.2 Generic Medicines**

A generic medicine can be defined in different ways (Birkett, D. J., 2003; Davit, et al., 2013; Dunne, et al., 2013). However, the term is easy to understand as defined by the WHO as "a pharmaceutical product, usually intended to be interchangeable with an innovator product, which is manufactured without a license from the innovator company and is marketed after the expiry date of the patent or other exclusive rights" (WHO, 2012b). The United States Food and Drug Administration (USFDA) define a generic drug product as "a drug product which is comparable to a reference (brand) listed drug product in dosage form, strength, route of administration, quality, performance characteristics, and intended use". Before registration, similar to all medicinal products including originator, generic drug products must pass through a rigorous registration process and stringent requirements to ensure their quality, safety and efficacy (USFDA, 2012).

In addition to these controls, the concept of bioequivalence is an essential requirement for any generic registration in many countries including Malaysia (Galgatte, et al., 2013). A bioequivalence study is performed to demonstrate a clinical equivalence between a generic product and its reference drug product to allow a bridging with the clinical studies conducted on the originator product. Hence, a repetition of preclinical or clinical studies is not required (European Medicines Agency, [EMA], 2010). A generic drug is expected to have the same clinical effect i.e. therapeutically equivalent and have a similar safety profile as the branded product when administered under the conditions specified in the labelling. Hence, generic drugs can be substituted for originator products by physicians and pharmacists (Levinson, D. R., 2008). Generic drugs are marketed under a non-proprietary or approved name rather than a proprietary or brand name. Generic drugs are as effective as branded drugs and are much more economical than originator brands (Matin, Y., 1999; Simoens, et al., 2006; Shafie, et al., 2008; WHO, 2011; Vogler, S., 2012a; European Generic Medicines Association [EGA], 2013a). Generic medicines are available as a standard therapy for many acute and chronic diseases (Sheppard, A., 2011; EGA, 2013a).

The Hatch-Waxman Act (1984) allows the entry of generic drugs into the market for trade, without conducting the expensive clinical trials, unlike their originator counterparts (Lewek, et al., 2010; Davit, et al., 2009; Bera, et al., 2012; Perkins, et al.). Hence, generic development costs are much lower; furthermore, they are being sold at a lower price when compared to originator brands. Generic drug manufacturers also have to follow similar strict quality standards with respect to identity, strength, quality, purity and potency. However, some variability can and

does occur during manufacturing, for both the originator and the generic products. When a drug product, generic or referenced, is mass-produced, very small variations in purity, size, strength, and other parameters are permitted. The USFDA limits the amount of variability that is acceptable. Both generic and branded products are being manufactured under similar cGMP conditions as those required for the innovator companies. All generic manufacturing, packaging, and testing sites, must pass the same quality standards as those of the branded drugs, and the generic products must meet the same specifications as any brand name product. In fact, many generic drugs are made in the same manufacturing plants as the brand name drug products. Hence, these low priced generics do not essentially construe to be of a lower quality. Generally, generics do not spend on costly advertising, marketing, and promotion. In addition, the availability of a single product, from multiple generic companies, creates competition in the market place, often resulting in price erosion (USFDA, 2012). The USFDA requirements for a bioequivalent generic drug product are as follows:

- a. It should have the same active ingredients and strength as the originator product.
- b. It should have the same dosage form and route of administration.
- c. It should be bioequivalent i.e. the same amount of the drug should be delivered in the same amount of time as that of the reference product.
- d. It should have the same labelling except for the name of the medication.
- e. It should have a documented chemistry, manufacturing steps, and quality control measures. The raw materials and finished product specifications should meet the United States Pharmacopoeia specifications.
- f. The potency and the shelf-life should be comparable to the reference product.

- g. The facilities used to manufacture, process, test, package and label the generic product should meet good manufacturing practices (GMP).

Thus, generics offer a simple and important solution to these expenditure issues, resulting in drug affordability, and the containment of pharmaceutical costs, since the price of medicines is a major component of healthcare costs (King, et al., 2002; Dukes, et al., 2003; Wallack, et al., 2004; Hassali, et al., 2009a; Godman, et al., 2010b; Hassali, et al., 2010; Simoens, S., 2010; Doloresco, et al., 2011; Al-Tamimi, et al., 2013; Hermansyah, A., 2013). Generic pharmaceuticals have now been cited as being a dependable lever to decrease healthcare costs and have continued to deliver outstanding savings to many developed countries. Genazzani, et al., stated that generic drugs are a major asset to national projects through the reduction of pharmaceutical expenses (Genazzani, et al., 2008). Apart from reducing healthcare costs, generic medication benefits include the reduction of a patient's out-of-pocket costs, and most importantly, to an increased adherence to the treatment regime (Shrank, et al., 2006; Shrank, et al., 2009a; Brems, et al., 2011; Iizuka, et al., 2011). With the use of generics, healthcare systems can save substantial amount of money which can be utilized to pay for more expensive patented and new innovative products that are required to treat some diseases where generics are not available (EGA, 2007). The savings from generics can also be utilized by policy makers or government to finance the research and development (R&D) and reimbursement of newer, expensive innovative medicines (Simoens, et al., 2006).

The advantages of generic medications can be listed as below:


- a. Reduction of the overall treatment cost for patients, resulting in the affordability and the containment of healthcare costs for governments.
- b. Increased adherence to therapy due to lower medicine costs.
- c. Stimulates innovation and the development of new drugs.
- d. Creates access to essential medicines and the continuity of supply.
- e. Economic development and employment.

Despite the above advantages of generic medicines, their use worldwide is lacking (Kirking, et al., 2001). The World Health Report (Chisholm, et al., 2010) has identified the following ten leading causes for health system inefficiency:

- a. Medicines - the use of sub standard medicine and counterfeits
- b. Medicines - inappropriate and ineffective use
- c. Medicines - underuse of generics
- d. Healthcare products & services - overuse
- e. Health workers - inappropriate or costly staff mix
- f. Healthcare services - inappropriate hospital admissions and length of stay
- g. Healthcare services - inappropriate hospital size
- h. Healthcare services - medical errors and suboptimal quality of care
- i. Health system leakages - waste, corruption & fraud
- j. Health interventions - inefficient strategies

Under use of generics was listed as one of the main reasons for healthcare system inefficiency.


Over the period 2003 to 2012, the USA has saved more than \$1.2 trillion from the healthcare system by using generics. In 2012 itself, the U. S. health system has saved \$217bn, up from \$188bn in 2011, due to the usage of generic medicines (Johnson, L. A., 2012; Generic Pharmaceutical Association, 2013). In 2012, savings, only from newer generic products (entering the market in the past 10 years), represent more than half of the total savings; which means that the use of generics in newer drugs will result in an exponential growth in savings (Figure 1.3).



**Figure 1.3 Generics Savings over the Course of Time in the USA**  
 [Adapted from the Generic Pharmaceutical Association, GPhA, USA]

In the US, generics account for approximately 75% of prescriptions, and this only incurs 13% of the total cost of newer, innovative, and generally more expensive medications (Kohl, et al., 2007). In Europe, it has been estimated that the use of generics is contributing almost €30bn every year to the healthcare system (Sheppard

A., 2011). Figure 1.4 depicts the market share of generics which differs a lot among the different European countries (Vogler S., 2012b).



**Figure 1.4 Generics Market Share of the Outpatient Market in the EU (% Volume) [Adapted from Vogler S., 2012b]**

The study conducted by Vogler, (2012b) in 16 European countries to discover the price differences between the originators and generics, for a selected basket of molecules, showed that an investment in generics tends to pay off (Vogler, S., 2012b). As per a recent WHO report, in the private sector of 17 countries, an average of 9% - 89% could be saved, by individual medicines, incurring a switch from the originator brand to the lowest priced generic equivalent (WHO, 2010a; Brems, et al., 2011; Kaplan, et al., 2012). In 2006, generics accounted for 42% of dispensed packs among 27 countries across Europe, but this cost was only 18% of the total pharmaceutical expenditure (Simoens, S., 2008a).



However, in order to get the maximum benefits from generics, it is really important to ensure that their availability, and immediate market entry, follows the patent expiration of the originator (Kanavos, et al., 2008; Fatokun, et al., 2011; Sheppard, A., 2011). The objective of generic medicines can be lost, or the results can be devastated, by a delayed or hindered entry into the market (Kesselheim, et al., 2006). In a study conducted by the European Commission (EC), it was estimated that almost €3bn was lost in 27 member countries, due to the delayed entry of generic versions of the top selling products between 2000 and 2007 (EC, 2009a).

Globally, governments across many countries have taken various initiatives to bring down their healthcare costs, which has led to lower reimbursed prices for generics and originators, as well as interchangeable brands, within the pharmacological or therapeutic classes (Godman, et al., 2008; Godman, et al., 2009a; Ferner, et al., 2010; McGinn, et al., 2010; Godman, et al., 2012a). The dispensing of generics was seen as a standard treatment, and this was planned through encouraging or mandating pharmacists, to substitute less expensive generic products, in place of the more expensive originators, wherever relevant, unless prohibited by physicians or the health authorities (Figueiras, et al., 2008; Seeley, et al., 2008; Simoens, S., 2008a). Preferential co-payment policies for generics in the US, among the insured population and seniors, have also resulted in a high utilisation of generics. As a result, generics account for approximately two thirds of prescriptions, but only 13% of costs (Kohl, et al., 2007; Shrank, et al., 2009a). Similar situations also occur in Asia. As an example, physicians working in government hospitals in Indonesia will soon be required to only prescribe generic drugs, unless there are no generic alternatives available (Bland, B., 2010).

### 1.2.1 Overview of Generic Drug Product Development Processes

The above brief discussion about generics describes a situation whereby generic medication refers to products that are no longer under patent protection. The entry of a generic drug product, following the patent expiration of originator, begins with the development of the generic drug product (Prasnikar, et al., 2006; Lionberger, R. A., 2008; Genazzani, et al., 2008). Different markets understand and use the term "generic drug" or "generic medicine", however, it is commonly understood to be as per the definition provided by the WHO to mean a pharmaceutical product which is:

- a. usually intended to be interchangeable with an innovator product
  - b. manufactured without a license from the originator company, and
  - c. marketed after the expiration date of the patent or other exclusive rights
- (Generic drugs, WHO).

Prasnikar, et al., explained that the generic development process initiation completes the manufacturing with a market entry of the product and is classified into 6 phases: phase 0 (generation of an idea), phase 1 (preliminary assessment), phase 2 (laboratory development), phase 3 (development of the technology), phase 4 (product registration), phase 5 (market launch).

**Phase 0** represents the selection of the probable generic candidates based upon many factors. Generally, large scale generic pharmaceutical companies will have a dedicated expert team, which will propose a list of potential generic molecules every year, as a proposal to initiate the next phase of activities (Prasnikar, et al., 2006).

**Phase 1** is a preliminary assessment phase, where drug molecules are assessed roughly for their market potential, patent expiry, complexities, the expenses involved, budgets, regulatory and intellectual property concerns, R&D and regulatory strategies, production feasibility and other commercial factors. This phase is the ‘desk research’ stage, involving all relevant documentation about the potential drug molecule, prior to the initiation of any practical activities in a laboratory (WHO, 2011). A risk based analysis is also conducted in order to introduce the new molecule in the development pipeline.

**Phase 2** starts in the development laboratory, with experimental work, which includes pre-formulation studies, formulation development, analytical method development, innovator characterisation, comparative dissolution studies, accelerated stability study work, pilot bioequivalence, and primary packaging development studies. At this stage, the scale up from the laboratorial to the semi-industrial scale is achieved (Prasnikar, et al., 2006; WHO, 2011).

**Phase 3** is the process or technology development phase. This phase includes the transference of product technology, to industry measurement, and the preparation of registration documentation. It includes clinical studies, toxicological studies, bioequivalence studies, and the completion of stability studies. This phase ends with the manufacturing of 3 registration or submission batches (Prasnikar, et al., 2006).


**Phase 4** is the registration of the product with a regulatory agency. The manufacturer files all of the documentation related to the product in a dossier, and replies to any

queries if any are raised by the regulatory agency during the course of the evaluation. This phase aims for obtaining marketing authorisation (Prasnikar, et al., 2006).

**Phase 5** is related to activities to be completed for the market launch of the product, which includes a launch requirement calculation, the ordering of raw materials and packaging materials, toolings etc., and ends with a final launch of the product (Prasnikar, et al., 2006).

As discussed earlier, generic drug product related registrations do not involve pre-clinical and clinical studies as required for the originator product. Alternatively, generics have to go through bioequivalence studies only, which are much cheaper than the clinical trials that are undertaken by the originators.

Figure 1.5 depicts that the main reason for generics being cheaper products is primarily due to their much lower investments when they are compared to the innovator products (Dunne, et al., 2013). However, the market price of a generic product can be considerably driven by the end-user and the prescription perception, local regulations, and reimbursement models (Simoens, S., 2007). Keeping in view the manufacturing costs, it should probably not differ significantly, as they (the generic and originator products) are both manufactured under the same standards, conditions, and the regulations in force as stated by the regulatory authorities. It should be noted that an originator product, can turn into a generic product, when the patent has expired, and this is very common these days. Since, the branded product becomes open to generic competition, after the patent expiry, and noticeable price erosions can be observed (Birkett, D. J., 2003).



**Figure 1.5 Schematic of the Drug Development Process [Adapted from Dunne, et al., 2013]**

### 1.2.2 Are Generics Really the Same as the Originator Products?

There have been, although, concerns with the effectiveness and the safety of generics (Himmel, et al., 2005; Kjoenniksen, et al., 2006; Heikkilä, et al., 2007; Kanavos, P., 2008; Simoens, S., 2008b; Figueiras, et al., 2009; Tsiantou, et al., 2009; Shrank, et

al., 2009a; Shrank, et al., 2009b; Chua, et al., 2010; Ferner, et al., 2010; McCartney, M., 2010; Sermet, et al., 2010), with some originator companies questioning the quality of generics, as part of their marketing strategies, to reduce the post-patent erosion of lost sales (EC, 2009b). However, concerns regarding generics generally only apply to a minority of situations (Kjoenniksen, et al., 2006; Shrank, et al., 2009a; Tsiantou, et al., 2009). There have been a substantial number of clinical studies conducted comparing a generic product with a reference product. Most of these studies have demonstrated the therapeutic equivalency between the generic and the branded drug product. In a recent review article, researchers reported the clinical data of 47 studies, which compared generic and reference products, for the treatment of heart and artery disease. These studies included some of the most frequently used medications that are globally available, like beta-blockers, diuretics, statins, and warfarin. These findings suggested that there is no evidence of a superiority of branded products, when compared to generic drugs, in measured clinical outcomes conducted in these studies (Kesselheim, et al., 2008).

In another study, 428 patients underwent implantation with a drug-eluting stent (DES) for coronary artery disease and were enrolled and then completed >1 year of clinical follow-up. Patients were divided into the following 2 groups, based on the treatment formulation, Platless® (test formulation, n=211), or Plavix® (reference formulation, n=217). The incidence of 1-year major adverse CVS, and cerebrovascular events (MACCEs), and stent thrombosis, were retrospectively reviewed. The result of the study proved that the two preparations of Clopidogrel showed similar rates of MACCEs (Park, et al., 2012).

Another multicenter study, which assessed the efficacy of a generic form of Atorvastatin in 119 patients, showed that Low Density Lipoprotein (LDL)-Cholesterol was reduced by 36.6% at four weeks and by 37.5% at eight weeks from the baseline. Total cholesterol and triglycerides were significantly reduced. There were no serious drug-related adverse events. It was concluded that the generic product Atorvastatin was safe and effective in the treatment of primary hypercholesterolemia (Punithavathi, et al., 2009).

Hence, there are many studies available, to prove this equivalency between generic and branded medicines. However, in spite of these studies, some physicians are concerned, because the bioequivalence studies, that predicate generics to be the equivalent, are not made public. They also have no access to find out about the differences in fillers, and other additives, which might change the rates of release. So it comes as no surprise that only 12 of 43 medical journal commentaries, on the subject of generic vs. brand medicines, encouraged the use of generics (Wegmann, J., 2010). Various reasons have been identified by researchers about the under utilisation of generics. Some physicians, pharmacists, and consumers, have expressed that bioequivalent generics, and branded medicines, may not be equivalent in their effects on various clinical parameters, including physiological measures, such as heart rate, or blood pressure, on important laboratory measurements, and various outcomes, such as health system utilisation, or mortality (Gaither, et al., 2001; Shrank, et al., 2009a). Narrow Therapeutic Index (NTI) drugs are of particular concern, where minor differences in plasma levels, can be less effective, or lead to toxicity (Banahan, et al., 1998). Originators have suggested that generics may be less effective or/and less safe than their branded counterparts. Anecdotes have appeared

in the lay press raising doubts about the efficacy and the safety of certain generic drugs (Saul, et al., 2007; Beck, M., 2008; Rockoff, J., 2008). There have also been concerns related to confusion, when patients are dispensed multiple branded generics, each with different names and appearance, which can potentially lead to medical errors (Godman, et al., 2009b; Decollogny, et al; 2011; Kesselheim, et al., 2014; Oyetunde, et al., 2014).

#### **1.2.2.1 Generic Substitution**

Generic medicines offer same health outcomes as they are clinically equivalent interchangeable medicines with originator products, but at a much cheaper cost (Godman, et al., 2010b). Generics are considered to be a cost-effective, first line or standard therapy for many diseases and conditions, such as hypertension, diabetes, hyperlipidaemia, hypercholesterolaemia, allergies, depression, gastrointestinal disorders, osteoporosis, infections, skin diseases etc. (Sheppard, A., 2011; EGA, 2013b). However, there has been concern raised with some NTI drugs, specifically due to switching or substituting them but not prescribing or dispensing them for the first time, currently there is no evidence of inferiority of generics. Currently, generic medicines are promoted as an integral part of healthcare systems (Al-Tamimi, et al., 2013), not only due to their affordability but also for sustainability of healthcare systems (Alrasheedy, et al., 2013). In order to promote generic medications, generic substitution (GS) and generic prescribing has been adopted by many healthcare systems (Vogler, S., 2012b). GS can be defined as an act of dispensing an equivalent generic medicine when an originator brand is prescribed (i.e. switching the patient from an originator product to an equivalent generic product), while generic



prescribing is defined as prescribing by the approved international non-proprietary name (INN) of the medicines (Ferner, et al., 2010). There are two aspects to consider regarding the use of generics: the ‘prescribability’ or ‘dispensability’ of generics (i.e. prescribing or dispensing generics for the first or initial patient prescription) and the ‘switchability’ or substitution (Rani, et al., 2004; Thiessen, J. J., 2005).

During a GS, there are many aspects that must be taken into consideration. The physician’s attitude towards GS is most often related to their general prescribing behaviour, their perception of therapeutic efficacy, their beliefs about generics, and their previous experience using generic alternatives, including any negative effects. Pharmacists may consider other kinds of issues like regulatory matters, the therapeutic class of the drug, the cost, and the bioequivalence information, when dispensing generic medication, as well as a patient’s medical and medication history, together with their acceptance to a change of brand. Also one need to consider patient’s preference, their consent, prescriber’s approval (if needed), patient’s understanding of the difference between the medicine brands to prevent any confusion due to brand changing (especially for elderly patients), consistency in the selection of the brand, especially for chronic and long-term therapy, the assessment of allergy history to any excipient, whether the new brand needs different instructions to be understood, and the patient’s familiarity with the brand (e.g. metered-dose dry-powder inhalers etc.) (International Society of Drug Bulletins, 2006; National Prescribing Service Limited, 2006; National Prescribing Service Limited, 2007; Duerden, et al., 2010). A patient’s concerns can be the drug’s efficacy, their overall satisfaction, the side effects, its appearance, in addition to their willingness to take medication, and every concern about managing their health

condition. Old aged patients do generally not prefer a change in their medicine or its appearance (Banahan, et al., 1997; Suh, D. C., 1999; Mott, et al., 2002; Kjoenniksen, et al., 2006; Best Practice Journal, 2007).

In addition, it is needed to educate patients about quality, safety, efficacy of generics and their bioequivalence, the similarities and differences between them against the originator product. The issues related with the usage of generics can be categorized with respect to the user as:

**i. Consumers: Major barriers to acceptance include:**

- a. Preference for a doctor's prescribed brand of medicine,
- b. Concern over the safety and the efficacy of generic medicine,
- c. Concern about the adverse effects from generic brands, and the confusion that may arise from different brands of the same medicine.

**ii. Prescribers/Pharmacists: Major barriers to acceptance include:**

- a. A possibility of patient confusion and a low level of confidence with generic medicine.
- b. Loyalty to the companies involved in R&D.
- c. A lack of knowledge on the issues surrounding bioequivalence testing for generic medicines.

Therefore, healthcare professionals need to assess the suitability of GS based on their professional judgment (USFDA, 2014). However, it is more important to note that the generic product must be bioequivalent and therapeutically equivalent to the

originator while GS. Thus, unlike other factors that need to be considered when performing GS, therapeutic equivalence should be based on scientific evidence rather than the professional judgement of individual healthcare professionals, as GS is not appropriate for some medicines (Duerden, et al., 2010; Ferner, et al., 2010; Lewek, et al., 2010; Holmes, et al., 2011). For example, NTI drugs such as antiarrhythmic drugs (e.g. digoxin), anti-epileptic drugs (e.g. carbamazepine), anticoagulant drugs (e.g. warfarin), and immunosuppressants (e.g. tacrolimus). Other examples include solid oral modified-release dosage forms of drugs like carbamazepine, diltiazem, morphine and oxycodone etc., medicines containing more than one active ingredient (e.g. oral contraceptives, antacid preparations containing simethicone), different products of the same active ingredient that have different licensed indications [e.g. sildenafil (Viagra® or Revatio®)], and products using different salts to form the active ingredients (e.g. nortriptyline) (Duerden, et al., 2010; Ferner, et al., 2010; Lewek, et al., 2010; Holmes, et al., 2011).

To avoid such situations, many countries have implemented regulatory guidelines to ensure that prescribing and substitution of generic products are appropriate. One such example is the *Approved Drug Products with Therapeutic Equivalence Evaluations*, commonly known as the 'Orange Book', which is a useful guide for pharmacists and other healthcare professionals with regards to therapeutic equivalence and approved generic products in the United States (USFDA, 2014). In Orange book, products that are therapeutically equivalent, where there is adequate evidence supporting bioequivalence, are designated with a code 'A', and products that are not therapeutically equivalent, where there is no adequate evidence supporting bioequivalence, are designated with a code 'B'.

Another example is from Australia, the *Schedule of Pharmaceutical Benefits (PBS)*, which is a useful guide for healthcare professionals and consumers regarding therapeutic equivalence between medicines (Department of Health and Ageing - Australia, 2007; Department of Health and Ageing - Australia, 2013). In this schedule, 'a' precedes the names of therapeutically equivalent and interchangeable medicine brands, whereas 'b' is attached to brands of medicines that are equivalent to the original brand but there is no evidence of equivalency between them. For other medicines not marked with 'a' or 'b', their therapeutic equivalence is not known; hence, caution should be exercised when GS is done. *British National Formulary* of United Kingdom is a useful tool for healthcare professionals when GS is not suitable for some medicines (Duerden, et al., 2010; Ferner, et al., 2010; Joint Formulary Committee, 2011). *The Royal Dutch Pharmacists Association (KNMP)* of The Netherlands has produced a professional guideline for community pharmacists regarding GS. This guideline provides principles and guidance to community pharmacists to perform GS appropriately. It also addresses the issue of NTI drugs and other drugs for which GS is not appropriate. Furthermore, it addresses random substitution and the general considerations and factors that need to be taken into account, such as the factors related to patients, prescribers and legal issues (Grandia, et al., 2012; KNMP, 2012).

There is ample evidence in literature for the necessity of having a formulary of interchangeable medicines to facilitate appropriate GS (Chong, et al., 2010a; Chua, et al., 2010; Johnston, et al., 2011; Hassali, et al., 2012a). Johnston, et al., (2011) recommended that evidence regarding therapeutic equivalence should be made available to the public and that best practice guidelines are required for GS

(Johnston, et al., 2011). Furthermore, Hassali, et al., (2012a) concluded that a formulary of interchangeable medicines must be developed to promote responsible GS. The formulary should also contain the list of the products that are not suitable for GS. Such a formulary would help both pharmacists and prescribers to assess the generic equivalence of the products offered as alternative substitutes (Hassali, et al., 2012a). In conclusion, it is essential to have a formulary of interchangeable products to guide responsible GS, to help healthcare professionals to be more confident when providing GS and to avoid situations where GS is inappropriate.

Many studies are available in the literature promoting the use of generics (Amit, et al., 2004; Araszkievicz, et al., 2008; Kesselheim, et al., 2008; Davit, et al., 2009; Punithavathi, et al., 2009; Kesselheim, et al., 2010; Park, et al., 2012), and are also reporting positively about the safety and the efficacy associated with the switching of products (Alessi-Severini, et al., 2006; Paton, C., 2006). On the contrary, there have been reports about a patient's concerns relating to generic medicine. These studies range from the qualitative assessment of the perceptions in specific patient populations (Bulsara, et al., 2010), to general consumer knowledge (Hassali, et al., 2009a; Figueiras, et al., 2010), versus the knowledge of professionals, which includes pharmacists and physicians (Babar, et al., 2011; Qunital, et al., 2012). Many of these studies focus on the influence of a relatively cheaper price of any prescriptions and the use of generic products (Heikkilä, et al., 2011a; Heikkilä, et al., 2011b; Heikkilä, et al., 2012). On the other hand, there have been many studies depicting the facts that consumers feel that a generic drug product is less effective when compared to the originator's medicine. There have also been studies reporting that the consumer responded well and then advanced in treatment when switched